Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at UCSD UCSF
Dates
study started
completion around

Description

Summary

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).

Official Title

A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects With Crohn's Disease

Keywords

Crohn's Disease (CD), Crohn's Disease, Efficacy, Safety, Tolerability, ABT-494, Crohn Disease, Upadacitinib

Eligibility

Locations

  • UC San Diego Health System /ID# 150041
    La Jolla California 92037 United States
  • Univ California, San Francisco /ID# 149987
    San Francisco California 94143-2204 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AbbVie
Links
This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
ID
NCT02782663
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 107 people participating
Last Updated